Predictive computer models designed to optimise HIV therapy in countries with limited healthcare resources have been published online. The models accurately predict how an individual on failing therapy will respond to any new combination of HIV drugs.

The risk of liver toxicity in people with HIV taking antiretroviral therapy and isoniazid preventive therapy for tuberculosis is strongly associated with either hepatitis B co-infection or pre-existing liver enzyme elevations, according to international research.

A recent study conducted in Botswana suggests that individuals whose partners provided more holistic, non-medical support, were more likely to be virally suppressed.

Positive results support the continued development of PRO 140 – CytoDyn’s investigational humanised monoclonal antibody for the treatment of patients with HIV who are failing their current ART regimens.

Within a week, the 'revolutionary' HIV drug dolutegravir has gone from being highly regarded to being the subject of international warnings. Health-e News reports that recent data from a Botswana study linking it to birth defects has seen the World Health Organisation,European Medicines Agency and the US Food and Drug Administration, unanimously issuing warnings statements.